Q32 Bio (QTTB) Amortization of Deferred Charges (2023 - 2026)
Q32 Bio's (QTTB) quarterly Amortization of Deferred Charges came in at $163000.0 in Q1 2026, up 239.58% year-on-year from $48000.0 in Q1 2025, and up 157.39% quarter-over-quarter from -$284000.0 in Q4 2025.
Q32 Bio (QTTB) Amortization of Deferred Charges (2023 - 2026) Analysis & Trends
Q32 Bio's Amortization of Deferred Charges history runs 4 years deep, the most recent figure standing at $163000.0 for Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges rose 239.58% year-over-year to $163000.0 in Q1 2026; TTM through Mar 2026 was $295000.0, a 192.08% increase from a year earlier, with the FY2025 full-year figure at $180000.0, down 7.22% from the prior year.
- Amortization of Deferred Charges improved to $163000.0 in Q1 2026 per QTTB's latest filing, from -$284000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $487000.0 in Q4 2023 and bottomed at -$284000.0 in Q4 2025.
- The 4-year median for Amortization of Deferred Charges is $133000.0 (2023), against an average of $83153.8.
- Biggest YoY gain for Amortization of Deferred Charges was 2000.0% in 2024; the steepest drop was 148.87% in 2024.
- Year by year, Amortization of Deferred Charges stood at $487000.0 in 2023, then tumbled by 148.87% to -$238000.0 in 2024, then decreased by 19.33% to -$284000.0 in 2025, then soared by 157.39% to $163000.0 in 2026.
- Per Business Quant, the three latest QTTB Amortization of Deferred Charges figures stand at $163000.0 (Q1 2026), -$284000.0 (Q4 2025), and $367000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn |
| 10 | Q32 Bio | 214.11 Mn | 163.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 163,000.00 |
| Mar 31, 2026 | 163,000.00 |
| Dec 31, 2025 | -284,000.00 |
| Dec 31, 2025 | -284,000.00 |
| Sep 30, 2025 | 367,000.00 |
| Sep 30, 2025 | 367,000.00 |
| Jun 30, 2025 | 49,000.00 |
| Jun 30, 2025 | 49,000.00 |
| Mar 31, 2025 | 48,000.00 |
| Mar 31, 2025 | 48,000.00 |
| Dec 31, 2024 | -238,000.00 |
| Dec 31, 2024 | -238,000.00 |
| Sep 30, 2024 | 147,000.00 |
| Sep 30, 2024 | 147,000.00 |
| Jun 30, 2024 | 144,000.00 |
| Jun 30, 2024 | 144,000.00 |
| Mar 31, 2024 | 141,000.00 |
| Mar 31, 2024 | 141,000.00 |
| Dec 31, 2023 | 487,000.00 |
| Dec 31, 2023 | 487,000.00 |